[
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
[og_img]
https://www.investing.com/news/press-releases/allogene-therapeutics-provides-updated-phase-1-data-highlighting-durable-responses-with-allo316-in-heavily-pretreated-advanced-renal-cell-carcinoma-at-asco-93CH-4074466
Investing.com
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Related articles